Liquid Biopsy Companies

Freenome

South San Francisco, United States

Freenome develops a blood-based, multiomics screening platform designed for early cancer detection, utilizing both genomic and proteomic biomarkers. Their core technology employs machine learning algorithms to analyze complex patterns in blood samples, aiming to detect cancer signals prior to symptom onset and improve screening accessibility. Currently focused on colorectal cancer with their CRC-DETECT test, Freenome is conducting clinical trials to validate performance and expand their platform to detect multiple cancer types, with a goal of increasing survival rates through earlier diagnosis.